Want to see MIST full AI Analyst Report?
Milestone Pharmaceuticals (MIST) Ratios
Milestone Pharmaceuticals Ratios
MIST's free cash flow for Q2 2026 was $-22.56M. For the 2026 fiscal year, MIST's free cash flow was decreased by $-25.67K and operating cash flow was $-22.53M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 8.01 | 9.10 | 10.11 | 11.70 | 17.55 |
| Quick Ratio | 7.96 | 9.10 | 10.11 | 11.70 | 17.55 |
| Cash Ratio | 5.23 | 3.12 | 1.90 | 1.24 | 16.85 |
| Solvency Ratio | -0.88 | -0.66 | -1.02 | -7.17 | -5.90 |
| Operating Cash Flow Ratio | -3.51 | -3.55 | -6.42 | -8.55 | -4.90 |
| Short-Term Operating Cash Flow Coverage | -75.80 | 0.00 | 0.00 | -106.00 | -148.32 |
| Net Current Asset Value | $ 40.13M | $ 11.57M | $ 14.58M | $ 63.67M | $ 111.67M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.51 | 0.73 | 0.69 | 0.03 | 0.01 |
| Debt-to-Equity Ratio | 1.40 | 4.17 | 3.09 | 0.04 | 0.01 |
| Debt-to-Capital Ratio | 0.58 | 0.81 | 0.76 | 0.04 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.58 | 0.80 | 0.75 | 0.00 | 0.00 |
| Financial Leverage Ratio | 2.72 | 5.74 | 4.49 | 1.12 | 1.06 |
| Debt Service Coverage Ratio | -13.18 | 10.56 | -22.33 | -117.78 | -191.88 |
| Interest Coverage Ratio | -16.28 | 11.76 | -23.92 | 0.00 | 0.00 |
| Debt to Market Cap | 0.34 | 0.36 | 0.69 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.74 | 0.82 | 1.26 | 0.06 | 0.02 |
| Net Debt to EBITDA | 0.25 | -0.78 | -0.67 | 0.09 | 2.64 |
| Profitability Margins | |||||
| Gross Profit Margin | 92.63% | 0.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -3852.85% | 0.00% | -5713.10% | -1167.76% | -287.15% |
| EBITDA Margin | -3845.47% | 0.00% | -5703.90% | -1165.98% | -286.53% |
| Operating Profit Margin | -4041.72% | 0.00% | -6109.80% | -1192.84% | -287.15% |
| Pretax Profit Margin | -4101.10% | 0.00% | -5968.50% | -1167.76% | -285.69% |
| Net Profit Margin | -4078.78% | 0.00% | -5968.50% | -1167.76% | -285.69% |
| Continuous Operations Profit Margin | -4078.78% | 0.00% | -5968.50% | -1167.76% | -285.69% |
| Net Income Per EBT | 99.46% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 101.47% | 98.62% | 97.69% | 97.90% | 99.49% |
| Return on Assets (ROA) | -55.53% | -54.99% | -79.34% | -78.39% | -35.76% |
| Return on Equity (ROE) | -150.97% | -315.81% | -355.88% | -88.00% | -38.06% |
| Return on Capital Employed (ROCE) | -62.75% | -62.49% | -89.85% | -87.27% | -38.09% |
| Return on Invested Capital (ROIC) | -62.00% | -61.97% | -89.13% | -86.64% | -38.02% |
| Return on Tangible Assets | -55.53% | -54.99% | -79.34% | -78.39% | -35.76% |
| Earnings Yield | -37.21% | -28.28% | -83.20% | -34.73% | -15.64% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.44 | 0.00 | 0.26 | 4.12 | 31.06 |
| Payables Turnover | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.18 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.94 | 0.00 | 0.46 | 1.87 | 16.20 |
| Asset Turnover | 0.01 | 0.00 | 0.01 | 0.07 | 0.13 |
| Working Capital Turnover Ratio | 0.02 | 0.00 | 0.02 | 0.06 | 0.12 |
| Cash Conversion Cycle | -15170.95 | 0.00 | 1405.62 | 88.55 | 11.75 |
| Days of Sales Outstanding | 828.21 | 0.00 | 1405.62 | 88.55 | 11.75 |
| Days of Inventory Outstanding | 2074.74 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 18073.90 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 2902.95 | 0.00 | 1405.62 | 88.55 | 11.75 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.58 | -0.46 | -1.08 | -1.24 | -0.79 |
| Free Cash Flow Per Share | -0.59 | -0.46 | -1.08 | -1.24 | -0.79 |
| Dividend Paid and CapEx Coverage Ratio | -162.39 | -874.18 | -414.50 | -192.90 | 0.00 |
| Capital Expenditure Coverage Ratio | -162.39 | -874.18 | -414.50 | -192.90 | 0.00 |
| Operating Cash Flow Coverage Ratio | -0.84 | -0.53 | -0.90 | -21.06 | -47.60 |
| Operating Cash Flow to Sales Ratio | -31.72 | 0.00 | -46.42 | -10.49 | -2.21 |
| Free Cash Flow Yield | -29.12% | -19.67% | -64.87% | -31.37% | -12.13% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.69 | -3.52 | -1.20 | -2.88 | -6.39 |
| Price-to-Sales (P/S) Ratio | 109.60 | 0.00 | 71.74 | 33.62 | 18.27 |
| Price-to-Book (P/B) Ratio | 4.06 | 11.17 | 4.28 | 2.53 | 2.43 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.43 | -5.08 | -1.54 | -3.19 | -8.25 |
| Price-to-Operating Cash Flow Ratio | -3.46 | -5.09 | -1.55 | -3.20 | -8.25 |
| Price-to-Earnings Growth (PEG) Ratio | -0.23 | 0.07 | -0.41 | -0.09 | 0.16 |
| Enterprise Value Multiple | -2.60 | -4.66 | -1.92 | -2.80 | -3.74 |
| Enterprise Value | 154.77M | 176.30M | 109.75M | 162.96M | 160.57M |
| EV to EBITDA | -2.60 | -4.66 | -1.92 | -2.80 | -3.74 |
| EV to Sales | 100.11 | 0.00 | 109.75 | 32.59 | 10.70 |
| EV to Free Cash Flow | -3.14 | -6.10 | -2.36 | -3.09 | -4.83 |
| EV to Operating Cash Flow | -3.16 | -6.11 | -2.36 | -3.11 | -4.83 |
| Tangible Book Value Per Share | 0.50 | 0.21 | 0.39 | 1.56 | 2.69 |
| Shareholders’ Equity Per Share | 0.50 | 0.21 | 0.39 | 1.56 | 2.69 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.02 | 0.00 | 0.02 | 0.12 | 0.36 |
| Net Income Per Share | -0.75 | -0.67 | -1.39 | -1.38 | -1.02 |
| Tax Burden | 0.99 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.06 | 1.09 | 1.04 | 1.00 | 0.99 |
| Research & Development to Revenue | 11.71 | 0.00 | 31.05 | 7.97 | 2.58 |
| SG&A to Revenue | 11.17 | 0.00 | 15.93 | 3.14 | 0.83 |
| Stock-Based Compensation to Revenue | 4.83 | 0.00 | 9.53 | 1.81 | 0.49 |
| Income Quality | 0.78 | 0.69 | 0.78 | 0.90 | 0.78 |
Currency in USD
